Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 447 • 2019 ACR/ARP Annual Meeting
Nail Abnormalities in a Cohort of Rheumatoid Arthritis Patients: Repetitive Trauma-Related Findings in Toenails Are Associated with Radiographic Damage
Virginia Pascual-Ramos¹, Silvia Méndez-Flores ¹, Judith Domínguez-Cherit ¹, Ana Gabriela Sánchez-Cárdenas ¹, Ana Barrera-Vargas ², Javier Merayo-Chalico ¹ and Irazú Contreras-Yáñez ¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico
Background/Purpose: Different dermatological changes and nail abnormalities have been reported in rheumatoid arthritis (RA) patients, some of which are specifically associated with the disease, while…
Abstract Number: 473 • 2019 ACR/ARP Annual Meeting
RA Presents in Disease Patterns Impacting Treatment Response
Kathryne Marks¹, Dana Symons ², Cynthia Crowson ³, Pamela Sinicrope ⁴ and Kelly O'Neill ⁵, ¹Rosalind Franklin University of Medicine and Science, Gurnee, IL, ²Rheumatoid Patient Foundation, Inc., Rockford, MI, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic, Rochester, MN, ⁵Rheumatoid Patient Foundation, Inc., Winter Springs, FL
Background/Purpose: Despite significant research on rheumatoid arthritis (RA), disease courses have not been clearly described. Like systemic lupus erythematosus and multiple sclerosis, RA displays a…
Abstract Number: 523 • 2019 ACR/ARP Annual Meeting
The Impact of Upadacitinib versus Methotrexate or Adalimumab on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis
Ronald van Vollenhoven¹, Andrew Östör ², Eduardo Mysler ³, Nemanja Damjanov ⁴, In-Ho Song ⁵, Yanna Song ⁶, Jessica Suboticki ⁵ and Vibeke Strand ⁷, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, ²Cabrini Medical Centre, Monash University, Malvern, Australia, Malvern, Australia, ³Organización Medica de Investigación, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, Belgrade, Serbia, ⁵AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁶AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁷Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: In Phase 3 trials, upadacitinib (UPA), an oral JAK1-selective inhibitor, has been assessed as monotherapy vs MTX (SELECT-EARLY1) and in combination with MTX vs…
Abstract Number: 819 • 2019 ACR/ARP Annual Meeting
The Long Noncoding RNA HOTTIP Regulates Cell Cycle and Inflammatory Response in Hand Synovial Fibroblasts
Mojca Frank-Bertoncelj ¹, Tadeja Kuret², Ana Županič ³, Snezna Sodin-Semrl ⁴, Oliver Distler ⁵ and Caroline Ospelt ¹, ¹University Hospital Zürich, Zürich, Switzerland, ²University Hospital Zürich, Zurich, Tajikistan, ³University Hospital Zürich, Zurich, Switzerland, ⁴University Medical Center Ljubljana, Ljubljana, Slovenia, ⁵Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Previously we showed that the long noncoding RNA (lncRNA) HOTTIP is exclusively expressed in synovial fibroblasts (SF) from distal joints, such as small joints…
Abstract Number: 926 • 2019 ACR/ARP Annual Meeting
Methotrexate Is Associated with Reduced Cardiovascular Risk in Rheumatoid Arthritis Independent of Disease Activity Modification
Tate Johnson¹, Joshua Baker ², Punyasha Roul ¹, Harlan Sayles ¹, Grant Cannon ³, Brian Sauer ³, Ted Mikuls ⁴ and Bryant England ⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ⁴VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁵VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of cardiovascular disease (CVD). Methotrexate (MTX), a mainstay in the treatment of RA, appears to mitigate…
Abstract Number: 1133 • 2019 ACR/ARP Annual Meeting
Medicare Spending (2012-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis
Deepan Dalal¹, Tingting Zhang ² and Theresa Shireman ², ¹Brown University, Riverside, RI, ²Brown University, Providence, RI
Background/Purpose: Biologic disease modifying agents (DMARDs) have become an integral part of rheumatoid arthritis (RA) treatment guidelines, but they are associated with a substantial increase…
Abstract Number: 1335 • 2019 ACR/ARP Annual Meeting
Tumor Necrosis Factor Alpha Inhibitor (TNF-α Inhibitor) Exposure and Risk of Hip Fracture in Veterans with Rheumatoid Arthritis: A Nested Case Control Study
Sarah Homann¹, Carlos Grijalva ¹, S. Bobo Tanner ¹ and James Morrow ¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Patients with rheumatoid arthritis (RA) have a much greater risk of sustaining a hip fracture than those without RA. Hip fractures cause significant morbidity…
Abstract Number: 1362 • 2019 ACR/ARP Annual Meeting
Relationship Between Waking Functions and Disease Activity in Rheumatoid Arthritis Patients Analyzed by Wearable Device
Masahiro Tada¹, Yutaro Yamada ², Koji Mandai ² and Noriaki Hidaka ¹, ¹Osaka City General Hospital, Osaka, Japan, ²Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: We reported that the prevalence of sarcopenia was 28% and locomotive syndrome was 52% in patients with rheumatoid arthritis (RA)1. It is unknown that…
Abstract Number: 1390 • 2019 ACR/ARP Annual Meeting
Prediction of Clinical Response to Abatacept in Rheumatoid Arthritis Patients Through the Determination of Anti-Carbamylated Proteins Antibodies Levels
Silvia Piantoni¹, Michele Boldini ¹, Rajesh Kumar ¹, Emirena Garrafa ¹, Chiara Bazzani ², Micaela Fredi ³, Ilaria Cavazzana ¹, Angela Tincani ³ and Franco Franceschini ³, ¹ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy, Brescia, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy
Background/Purpose: Carbamylation is a non-enzymatic irreversible post-translational modification of proteins. The presence of anti-carbamylated protein antibodies (anti-CarP) has been observed in rheumatoid arthritis (RA). In…
Abstract Number: 1427 • 2019 ACR/ARP Annual Meeting
Comparison of Real-World Persistence of Subcutaneously Administered Biologic Disease-Modifying Antirheumatic Drug Therapies Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Jennie Best¹, Lenore Tominna ¹ and Ibrahim Abbass ¹, ¹Genentech, Inc., South San Francisco, CA
Background/Purpose: The EULAR and ACR clinical guidelines recommend switching to a different disease-modifying antirheumatic drug (DMARD) when biologic-treated patients experience treatment failure or toxicity. Lack…
Abstract Number: 1858 • 2019 ACR/ARP Annual Meeting
Beta-2-Glycoprotein-I IgA Antibodies Predict Coronary Plaque Burden, Progression and Moderate the Effect of Inflammation on Atherosclerosis in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth ¹, Elizabeth Hernandez ¹, Viet Bui ¹ and Matthew Budoff ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA
Background/Purpose: Beta-2-glycoprotein-I(b2GPI), an apolipoprotein abundant in plasma, is readily expressed in human atherosclerotic plaque. Anti-b2GPI-IgA antibodies (Ab) have been previously reported in both rheumatoid arthritis…
Abstract Number: 1940 • 2019 ACR/ARP Annual Meeting
Investigating the Post-Partum Flare in Rheumatoid Arthritis Using Transcriptome Analysis
Matthew Wright¹, Dana Goin ², Mette Smed ³, Lior Pachter ⁴, J. Lee Nelson ⁵, Nicholas Jewell ⁶, Jørn Olsen ⁷, Merete Lund Hetland ⁸, Vibeke Zoffmann ⁹ and Damini Jawaheer ¹⁰, ¹UCSF Benioff Children's Hopsital Oakland, Oakland, ²UCSF Benioff Children's Hospital Oakland, Oakland, ³Juliane Marie Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ⁴Caltech, Pasadena, ⁵Fred Hutchinson Cancer Research Center, Seattle, ⁶University of California Berkeley, Berkeley, ⁷Aarhus University Hospital, Aarhus, Denmark, ⁸DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ⁹Juliane Marie Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, ¹⁰UCSF Benioff Children's Hospital Oakland, Oakland, CA
Background/Purpose: Women with Rheumatoid arthritis (RA) tend to have a predictable flare of disease activity in the months after childbirth. The mechanism(s) underlying this post-partum…
Abstract Number: 2094 • 2019 ACR/ARP Annual Meeting
Evaluation of Influenza and Pneumococcal Vaccination Rate in Patients with Rheumatoid Arthritis and Spondyloarthritis, and the Attitudes of Rheumatologists About Vaccination
İdil Kurut Aysin ¹, Murat Aysin ², Dilek Solmaz ³, Nazmiye Baş Tomas ⁴, Filiz Koç ⁴, Elif Durak Ediboğlu ⁴, Gokhan Kabadayi ⁵, Onay Gercik ³, Sercan Gücenmez ⁴ and Servet Akar⁶, ¹Izmir Katip Celebi University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²University of Izmir Katip Celebi Faculty of Medicine, Public Health, İzmir, Turkey, ³Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ⁴University of Izmir Katip Celebi Faculty of Medicine, Rheumatology, İzmir, Turkey, ⁵Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ⁶Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey
Background/Purpose: Patients with inflammatory arthritis have increased risk of infections which may lead to morbidity and mortality. Some of those infections could be prevented by…
Abstract Number: 2259 • 2019 ACR/ARP Annual Meeting
Physical Challenges in RA: A Qualitative Study of an Online Patient Support Group
Jude des Bordes ¹, Jessica Foreman ¹, Maria Lopez-Olivo¹, Susan K Peterson ¹, Tiffany Westrich-Robertson ², Catherine Hofstetter ³, Anne Lyddiatt ⁴, Amye Leong ⁵ and Maria E. Suárez-Almazor ⁶, ¹The University of Texas, MD Anderson Cancer Center, Houston, TX, ²International Foundation for Autoimmune and Autoinflammatory Arthritis, Saint Louis, MO, ³Patient advocate, Toronto, ON, Canada, ⁴Musculoskeletal Group, Cochrane Collaboration, Toronto, ON, Canada, ⁵7. Healthy Motivation and the Global Alliance for Musculoskeletal Health of the Bone and Joint Decade, Santa Barbara, CA, ⁶Department of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX , USA., Houston, TX
Background/Purpose: Patients with rheumatoid arthritis (RA) face a number of challenges which adversely affect their quality of life. The objective was to qualitatively evaluate content…
Abstract Number: 2315 • 2019 ACR/ARP Annual Meeting
Association of Rheumatic Autoimmune Disease, Including Rheumatoid Arthritis, with Post-Traumatic Stress Disorder but Not Traumatic Brain Injury in Veterans
Biji Kurien ¹, Calin Prodan ² and Robert Scofield¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Neurology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Autoimmune diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus, are 2- to 3-fold more common among those with post-traumatic stress disorder (PTSD) than…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.